2025-06-04 – Press Releases – www.prnewswire.com
Agreement focuses on advancing armored and bi-specific CAR-γδTs for AML and multiple myeloma LEXINGTON, Mass. and SINGAPORE, June 4, 2025 /PRNewswire/ — Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today…
